MetaCap

Molecular Partners (MOLN) vs Outlook Therapeutics (OTLK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Molecular Partners (MOLN) has outperformed Outlook Therapeutics (OTLK) over the past year, losing 37.5% versus a loss of 79.3%. Over five years, MOLN leads with a -77.9% price change compared with -98.6% for OTLK. Molecular Partners is the larger company by market cap ($96.8 million vs $94.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MOLN-37.50%OTLK-79.26%
+37%-29%-96%
Nov 21, 20251 yearNov 20, 2026
MOLN-75.84%OTLK-98.73%
+220%+53%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MOLN versus OTLK key metrics
MetricMOLNOTLK
Share price$2.53$0.39
Market cap$96.80M$94.94M
1-day change-5.25%-2.74%
YTD return-42.07%-75.32%
1-year return-37.50%-79.26%
5-year return-77.87%-98.58%
EPS (TTM)$-1.68$-0.70
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.41M
Net income (latest FY)—$-62.42M
Gross margin—4.05%
Operating margin—-4744.25%
Net margin—-4416.22%
52-week high$5.36$2.54
52-week low$2.52$0.161
Distance from 52-week high-52.89%-84.63%
Analyst consensusstrong_buynone
Avg. price target upside+295.64%+1189.74%
Average volume1.63K4.60M
Shares outstanding38.34M243.45M
Employees13417
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MOLN has outperformed OTLK by 41.8 percentage points over the past year.

About Molecular Partners

MOLN stock →

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

About Outlook Therapeutics

OTLK stock →

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees

MOLN vs OTLK FAQ

Which is bigger, Molecular Partners or Outlook Therapeutics?

Molecular Partners (MOLN) is larger, with a market capitalization of $96.80M compared with $94.94M for Outlook Therapeutics (OTLK).

Which stock has performed better over the past year, MOLN or OTLK?

MOLN returned -37.50% over the past 12 months, compared with -79.26% for OTLK (price return, excluding dividends). Past performance does not predict future results.

Are Molecular Partners and Outlook Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons